Literature DB >> 14972776

Pharmacological mechanisms of naltrexone and acamprosate in the prevention of relapse in alcohol dependence.

John Littleton1, Walter Zieglgänsberger.   

Abstract

Naltrexone and acamprosate may ultimately prove to be useful additions to pharmacotherapy for alcoholism by reducing relapse. Naltrexone is a relatively selective competitive antagonist at mu-opioid receptors, and this activity may explain its anti-relapse action either because endogenous opioids are involved in the positively reinforcing effects of alcohol and/or because these same transmitters are involved in the conditioned anticipation of these effects. In contrast, the pharmacology of acamprosate is still poorly understood. This is not surprising because it is a small flexible molecule with similarities to several neuro-active amino acids and is used in high doses. All these factors suggest that it may have multiple actions. Currently, the best explanation for the effects of acamprosate seems to be that it inhibits the glutamatergic transmitter system involved in both the negative reinforcing effects of alcohol and the conditioned "pseudo-withdrawal" that may be important in cue-induced relapse.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14972776     DOI: 10.1111/j.1521-0391.2003.tb00492.x

Source DB:  PubMed          Journal:  Am J Addict        ISSN: 1055-0496


  35 in total

1.  Pharmacologically induced alcohol craving in treatment seeking alcoholics correlates with alcoholism severity, but is insensitive to acamprosate.

Authors:  John C Umhau; Melanie L Schwandt; Julie Usala; Christopher Geyer; Erick Singley; David T George; Markus Heilig
Journal:  Neuropsychopharmacology       Date:  2011-02-02       Impact factor: 7.853

Review 2.  Hepatitis infection in the treatment of opioid dependence and abuse.

Authors:  Thomas F Kresina; Diana Sylvestre; Leonard Seeff; Alain H Litwin; Kenneth Hoffman; Robert Lubran; H Westley Clark
Journal:  Subst Abuse       Date:  2008-04-28

Review 3.  Neural substrates of cue reactivity: association with treatment outcomes and relapse.

Authors:  Kelly E Courtney; Joseph P Schacht; Kent Hutchison; Daniel J O Roche; Lara A Ray
Journal:  Addict Biol       Date:  2015-10-04       Impact factor: 4.280

4.  Baclofen blocks expression and sensitization of anxiety-like behavior in an animal model of repeated stress and ethanol withdrawal.

Authors:  Darin J Knapp; David H Overstreet; George R Breese
Journal:  Alcohol Clin Exp Res       Date:  2007-04       Impact factor: 3.455

5.  High Drinking in the Dark (HDID) mice are sensitive to the effects of some clinically relevant drugs to reduce binge-like drinking.

Authors:  John C Crabbe; Angela R Ozburn; Pamela Metten; Amanda Barkley-Levenson; Jason P Schlumbohm; Stephanie E Spence; Wyatt R Hack; Lawrence C Huang
Journal:  Pharmacol Biochem Behav       Date:  2017-08-05       Impact factor: 3.533

Review 6.  Pharmacotherapeutic management of co-morbid alcohol and opioid use.

Authors:  Lauren E Hood; Jonna M Leyrer-Jackson; M Foster Olive
Journal:  Expert Opin Pharmacother       Date:  2020-02-27       Impact factor: 3.889

7.  Extended-release naltrexone reduces alcohol consumption among released prisoners with HIV disease as they transition to the community.

Authors:  Sandra A Springer; Angela Di Paola; Marwan M Azar; Russell Barbour; Archana Krishnan; Frederick L Altice
Journal:  Drug Alcohol Depend       Date:  2017-03-10       Impact factor: 4.492

Review 8.  Acamprosate: a review of its use in the maintenance of abstinence in patients with alcohol dependence.

Authors:  Lesley J Scott; David P Figgitt; Susan J Keam; John Waugh
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

9.  Pharmacogenetics of naltrexone in asian americans: a randomized placebo-controlled laboratory study.

Authors:  Lara A Ray; Spencer Bujarski; Pauline F Chin; Karen Miotto
Journal:  Neuropsychopharmacology       Date:  2011-09-07       Impact factor: 7.853

10.  Integrated Management of Physician-delivered Alcohol Care for Tuberculosis Patients: Design and Implementation.

Authors:  Shelly F Greenfield; Alan Shields; Hilary Smith Connery; Viktoriya Livchits; Sergey A Yanov; Charmaine S Lastimoso; Aivar K Strelis; Sergey P Mishustin; Garrett Fitzmaurice; Trini A Mathew; Sonya Shin
Journal:  Alcohol Clin Exp Res       Date:  2009-11-20       Impact factor: 3.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.